Related Experiment Video
Updated: May 28, 2025

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
Published on: September 1, 2019
De novo RUNX1-driven acute myeloid leukemia requiring integrative genetics
Celeste C Eno1, Jeremy Lorber2, Eric Vail1
1Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Abstract:
Copy number variants are common in myeloid malignancies and may hold diagnostic, prognostic or therapeutic significance. We present a case of acute myeloid leukemia driven by a RUNX1 deletion with no prior history of a myeloid neoplasm. Discovery of the underlying genetic lesion required multiple testing platforms highlighting the strengths and weaknesses of each test type. Additionally, this case adds to the literature of RUNX1 deletion AML, the adverse prognosis that these cases share and the potential consideration of RUNX1 alterations (both deletions and mutations) as a specific AML entity.
Related Concept Videos
Exon Recombination
Exon shuffling follows “splice frame rules.” Each exon...
Inheritance of Chromatin Structures

